← Back to Search

Local Anesthetic

Nerve Block with Bupivacaine an for Musculoskeletal Pain

Phase 4
Waitlist Available
Led By Sergey Motov, MD
Research Sponsored by Antonios Likourezos
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights

Summary

The project is meant to evaluate the effect of a combination of medications (Bupivacaine + Ketamine) used in an ultra-sound guided nerve block for patients presenting to the Emergency Department (ED) with hip and/or femur fractures. The goal is to see whether the combination of these two medications will result in greater and longer-lasting pain relief, longer-lasting motor and sensory block and overall less need for opioid rescue analgesia.

Eligible Conditions
  • Musculoskeletal Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
time to first rescue analgesia post-regional nerve blockade
Secondary study objectives
Pain score at 30 minutes

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Nerve Block with Bupivacaine anExperimental Treatment2 Interventions
Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
Group II: Nerve Block with Bupivacaine alActive Control1 Intervention
Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

Antonios LikourezosLead Sponsor
39 Previous Clinical Trials
8,494 Total Patients Enrolled
1 Trials studying Musculoskeletal Pain
60 Patients Enrolled for Musculoskeletal Pain
Sergey Motov, MDPrincipal InvestigatorMaimonides Medical Center
17 Previous Clinical Trials
1,595 Total Patients Enrolled
1 Trials studying Musculoskeletal Pain
60 Patients Enrolled for Musculoskeletal Pain
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top